12. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485.
13. Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leuke-mia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. Journal of Clinical Oncology.
2009;27(28):4747–4753.
14. Becker H, Marcucci G, Maharry K, et al. Favorable prognos-tic impact of NPM1 mutations in older patients with cytoge-netically normal de novo acute myeloid leukemia and associ-ated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology.
2010;28(4):596–604.
15. Pastore F, Dufour A, Benthaus T, et al. Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogeneti-cally Normal Acute Myeloid Leukemia. Journal of Clinical Oncol-ogy. 2014.
16. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
Journal of Clinical Oncology. 2011;29(5):475–486.
17. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diag-nosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood.
2009;113(1):28–36.
18. Malfuson J-V, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93(12):1806–1813.
19. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or ad-vanced myelodysplastic syndrome. Leukemia. 2004;18(4):809–
816.
20. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598–
605.
21. Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000–2008.
22. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive che-motherapy in 998 patients age 65 years or older with acute my-eloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–1098.
23. Sorror ML, Maris MB, Storer BE, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative con-ditioning: influence of pretransplantation comorbidities. Blood.
2004;104(4):961–968.
Study Inclusion criteria Age (years) ORR OS
months 1-year Early Death rate 30-days 60-days Quizartinib Phase I
Cortes et al (2013) n=76
relapsed/refractory Median 60
first-line vs 3+7 IC 60-75 CR 66.7%
vs 51.2%
(p=0.07)
14.7 m – 3.5% 4.7%
Lenalidomide Phase II
Fehniger et al (2011) n= 33
first-line 71
(range 60-88) 30%
(CR/CRi) – 18% 24% 27%
Lenalidomide
+ Azacitidine Phase I-II
Pollyea et al (2013) n= 45
first-line 74
relapsed/refractory 71 28% (CR/CRi) – – – –
w=weeks; m=months; CR=Complete Remission; CRi=CR without complete counts recovery; HI=hematological Improvement; PR=partial remission;
nr= not reported; OS= Overall Survival; n= total number of patients; Ara-C= cytarabine; AZA= azacitidine; DAC= decitabine.
Table 2. New treatment agents in elderly AML
SCHWERPUNKTTHEMA
24. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome pre-dictor for patients with acute myeloid leukemia in first remis-sion: combined FHCRC and MDACC experiences. Blood.
2007;110(13):4606–4613.
25. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving in-duction therapy for acute myeloid leukaemia. Br J Haematol.
2007;136(4):624–627.
26. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment pre-dicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–
4294.
27. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. Journal of Clinical Oncology.
2007;25(14):1824–1831.
28. Ziogas DC, Voulgarelis M, Zintzaras E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther. 2011;33(3):254–279.
29. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Seminars in Oncology. 2008;35(4):430–438.
30. Hills RK, Burnett AK. Applicability of a «Pick a Winner» trial design to acute myeloid leukemia. Blood. 2011;118(9):2389–
2394.
31. Schlenk RF, Fröhling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18(11): acute myeloid leukemia. Blood. 2013;121(1):26–28.
34. Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in in-duction treatment improves the outcome of adult patients young-er than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. Journal of Clinical Oncology.
2014;32(3):219–228.
35. Büchner T, Hiddemann W, Berdel W, et al. Acute myeloid leu-kemia: treatment over 60. Rev Clin Exp Hematol. 2002;6(1):46–
59– discussion 86–7.
36. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose in-tensification in acute myeloid leukemia. N Engl J Med.
2009;361(13):1249–1259.
37. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–1248.
38. Pautas C, Merabet F, Thomas X, et al. Randomized study of in-tensified anthracycline doses for induction and recombinant inter-leukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. Journal of Clinical Oncology. 2010;28(5):808–814.
39. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood.
1992;79(8):1924–1930.
40. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896–903.
41. Baer MR, George B, Sanford BL, et al. Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. ASCO 2010.
42. Itzykson R, Gardin C, Pautas C, et al. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid
leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica.
2011;96(6):837–844.
43. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to im-prove treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Re-search Council AML11 trial. Blood. 2001;98(5):1302–1311.
44. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129–5135.
45. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone ver-sus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16(3):872–881.
46. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete re-mission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology. 2008;26(30):4934–4939.
47. Schlenk RF, Fröhling S, Hartmann F, et al. Intensive consolida-tion versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial. Leukemia.
2006;20(4):748–750.
48. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European Leu-kemiaNet AML Working Party consensus statement on alloge-neic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012.
49. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodys-plastic syndrome in patients not considered fit for intensive treat-ment. Cancer. 2007;109(6):1114–1124.
50. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):
272–279.
51. Lübbert M, Rüter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Hae-matologica. 2012;97(3):393–401.
52. Cashen AF, Schiller GJ, O'Donnell MR, Dipersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Journal of Clinical Oncol-ogy. 2010;28(4):556–561.
53. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences. 2010;107(16):7473–7478.
54. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 2012;30(21):2670–2677.
55. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma.
2012;53(1):110–117.
LEUKÄMIE/LYMPHOME
56. Passweg JR, Pabst T, Blum S, et al. Azacytidine for acute my-eloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Leuk Lymphoma. 2014;55(1):87–91.
57. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regi-mens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology. 2010;28(4):
562–569.
58. Pleyer L. Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. 2012;1–2.
59. Lancet JE. New agents: great expectations not realized. Best Pract Res Clin Haematol. 2013;26(3):269–274.
60. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute my-eloid leukemia: a remarkable saga about an active drug. Blood.
2013;121(24):4838–4841.
61. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood.
2013;121(24):4854–4860.
62. Li X, Xu SN, Qin DB, et al. Effect of adding gemtuzumab ozo-gamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Annals of Oncology. 2014;25(2):455–461.
63. Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more:
results of a multicenter phase 3 study. Blood. 2010;115(13):
2586–2591.
64. Burnett AK, Hills RK, Hunter AE, et al. The addition of gem-tuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2012;27(1):
75–81.
65. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozo-gamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Lancet. 2012.
66. Amadori S, Suciu S, Stasi R, et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA con-sortium (AML-17). Journal of Clinical Oncology. 2013;31(35):
4424–4430.
67. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clo-farabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Jour-nal of Clinical Oncology. 2010;28(4):549–555.
68. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute my-eloid leukemia and high-risk myelodysplastic syndrome. Blood.
2008;112(5):1638–1645.
69. Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine al-ternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012;118(18):4471–4477.
70. Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122(8):1384–1394.
71. Cortes JE, Kantarjian H, Foran JM, et al. Phase I Study of Quizar-tinib Administered Daily to Patients With Relapsed or Refrac-tory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status. Journal of Clinical Oncology. 2013.
72. Lancet JE, Cortes JE, Hogge DE, et al. Phase II, multicenter, ran-domized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age. Blood. 2014.
73. Kantarjian H, Faderl S, Garcia-Manero G, et al. Oral sapac-itabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012;13(11):
1096–1104.
74. Pollyea DA, Zehnder J, Coutré S, et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013;98(4):591–596.
75. Visani G, Ferrara F, Di Raimondo F, et al. Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.
Leukemia. 2014;28(4):967–970.
76. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hy-droxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060–1066.
77. Mawad R, Becker P, Hendrie P. A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leu-kemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS).
2013;1–2.
78. DiNardo C, Kantarjian HM, Ravandi F. A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. 2013;1–2.
79. Savona M, Garzon R, de Nully Brown P. Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelog-enous Leukemia (AML). 2013;1–2.
80. Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117(6):1828–1833.
81. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013;14(4):354–362.
Correspondence:
PD Dr. med. Georg Stüssi Division of Hematology
Oncology Institute of Southern Switzerland CH-6500 Bellinzona
georg.stuessi@eoc.ch